The rekovelle market research report is one of a series of new reports that provides rekovelle market statistics, including the rekovelle industry global market size, regional shares, competitors with the rekovelle market share, detailed rekovelle market segments, market trends, and opportunities, and any further data you may need to thrive in the rekovelle industry. This rekovelle market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the rising incidence of genetic diseases, rising prevalence of hormonal disorders, growing adoption of IVF worldwide, growing number of IVF centers and fertility clinics, and increasing prevalence of hypogonadism. Major trends in the forecast period include integration with fertility preservation, advancements in HRT products, technological innovations and advanced IVF equipment, technological advancements in fertility treatments, and integration of TRT with other wellness and anti-aging therapies.
The rising prevalence of infertility is expected to drive the growth of the rekovelle market in the future. Infertility refers to the inability of couples or individuals to conceive after one year of regular, unprotected sexual intercourse. The increasing rates of infertility are attributed to factors such as delayed childbearing, lifestyle changes, exposure to environmental toxins, and underlying medical conditions, all contributing to higher demand for fertility treatments. Rekovelle aids in reducing infertility by improving ovarian response, which enhances the success of assisted reproductive technologies such as IVF, increasing the chances of successful fertilization and pregnancy. For example, in April 2023, the World Health Organization reported that approximately 17.5% of the global adult population, or about 1 in 6 individuals, face infertility. As a result, the growing prevalence of infertility is driving the expansion of the rekovelle market.
The increasing adoption of personalized medicine is also expected to fuel the growth of the rekovelle market. Personalized medicine tailors treatment based on an individual’s genetic makeup, lifestyle, and environmental factors, optimizing the effectiveness of treatment and minimizing potential side effects. The rising adoption of personalized medicine is supported by advancements in genomics, increased availability of genetic testing, and a greater demand for targeted therapies that improve patient outcomes. Rekovelle contributes to this trend by offering individualized dosing based on a woman’s body weight and ovarian reserve, helping to optimize fertility treatments for improved outcomes in IVF cycles. For example, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from six approvals in 2022. Therefore, the growing adoption of personalized medicine is contributing to the growth of the rekovelle market.
A key trend in the rekovelle market is the ongoing study of the drug to enhance its application as a personalized treatment for ovarian stimulation. These studies focus on evaluating its efficacy, safety, and optimal usage in both clinical and real-world settings to improve personalized treatment outcomes. In March 2023, Ferring Pharmaceuticals presented the results of the PROFILE study, which was the first prospective, real-world study of Rekovelle (follitropin delta). The findings showed that approximately 74% of participants had between 4 and 19 oocytes retrieved, with ongoing pregnancy rates consistent with those seen in previous Phase 3 trials. Notably, 95% of the cases used an individualized dosing algorithm based on body weight and anti-Müllerian hormone levels. These results underscore Rekovelle’s efficacy and safety, reinforcing its value as a personalized treatment for ovarian stimulation in real-world IVF settings.
The countries covered in the rekovelle market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Rekovelle is a fertility medication that contains the recombinant hormone follitropin delta. It is used to stimulate ovarian follicle development in women undergoing in vitro fertilization (IVF). By promoting the production of multiple eggs, it increases the chances of successful fertilization and pregnancy.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for rekovelle include controlled ovarian stimulation and polycystic ovary syndrome. Controlled ovarian stimulation (COS) is a fertility treatment where hormones are administered to stimulate the ovaries to produce multiple eggs for fertilization, typically as part of IVF. Rekovelle is distributed through various channels, including hospitals, clinics, and pharmacies, and is used by a range of patients, including pediatric, adult, and geriatric populations.
The rekovelle market consists of sales of products including injections, pre-filled syringes, vials, and dose adjuster kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the rising incidence of genetic diseases, rising prevalence of hormonal disorders, growing adoption of IVF worldwide, growing number of IVF centers and fertility clinics, and increasing prevalence of hypogonadism. Major trends in the forecast period include integration with fertility preservation, advancements in HRT products, technological innovations and advanced IVF equipment, technological advancements in fertility treatments, and integration of TRT with other wellness and anti-aging therapies.
The rising prevalence of infertility is expected to drive the growth of the rekovelle market in the future. Infertility refers to the inability of couples or individuals to conceive after one year of regular, unprotected sexual intercourse. The increasing rates of infertility are attributed to factors such as delayed childbearing, lifestyle changes, exposure to environmental toxins, and underlying medical conditions, all contributing to higher demand for fertility treatments. Rekovelle aids in reducing infertility by improving ovarian response, which enhances the success of assisted reproductive technologies such as IVF, increasing the chances of successful fertilization and pregnancy. For example, in April 2023, the World Health Organization reported that approximately 17.5% of the global adult population, or about 1 in 6 individuals, face infertility. As a result, the growing prevalence of infertility is driving the expansion of the rekovelle market.
The increasing adoption of personalized medicine is also expected to fuel the growth of the rekovelle market. Personalized medicine tailors treatment based on an individual’s genetic makeup, lifestyle, and environmental factors, optimizing the effectiveness of treatment and minimizing potential side effects. The rising adoption of personalized medicine is supported by advancements in genomics, increased availability of genetic testing, and a greater demand for targeted therapies that improve patient outcomes. Rekovelle contributes to this trend by offering individualized dosing based on a woman’s body weight and ovarian reserve, helping to optimize fertility treatments for improved outcomes in IVF cycles. For example, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from six approvals in 2022. Therefore, the growing adoption of personalized medicine is contributing to the growth of the rekovelle market.
A key trend in the rekovelle market is the ongoing study of the drug to enhance its application as a personalized treatment for ovarian stimulation. These studies focus on evaluating its efficacy, safety, and optimal usage in both clinical and real-world settings to improve personalized treatment outcomes. In March 2023, Ferring Pharmaceuticals presented the results of the PROFILE study, which was the first prospective, real-world study of Rekovelle (follitropin delta). The findings showed that approximately 74% of participants had between 4 and 19 oocytes retrieved, with ongoing pregnancy rates consistent with those seen in previous Phase 3 trials. Notably, 95% of the cases used an individualized dosing algorithm based on body weight and anti-Müllerian hormone levels. These results underscore Rekovelle’s efficacy and safety, reinforcing its value as a personalized treatment for ovarian stimulation in real-world IVF settings.
The key company operating in the rekovelle market is Ferring Pharmaceuticals A/S
Europe was the largest region in the rekovelle market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rekovelle report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the rekovelle market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Rekovelle is a fertility medication that contains the recombinant hormone follitropin delta. It is used to stimulate ovarian follicle development in women undergoing in vitro fertilization (IVF). By promoting the production of multiple eggs, it increases the chances of successful fertilization and pregnancy.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for rekovelle include controlled ovarian stimulation and polycystic ovary syndrome. Controlled ovarian stimulation (COS) is a fertility treatment where hormones are administered to stimulate the ovaries to produce multiple eggs for fertilization, typically as part of IVF. Rekovelle is distributed through various channels, including hospitals, clinics, and pharmacies, and is used by a range of patients, including pediatric, adult, and geriatric populations.
The rekovelle market consists of sales of products including injections, pre-filled syringes, vials, and dose adjuster kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Rekovelle Market Characteristics4. Rekovelle Market Trends And Strategies5. Rekovelle Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Rekovelle Pricing Analysis & Forecasts30. Global Rekovelle Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Rekovelle Market32. Recent Developments In The Rekovelle Market
3. Rekovelle Market Biologic Drug Characteristics
6. Global Rekovelle Growth Analysis And Strategic Analysis Framework
8. Rekovelle Market Segmentation
9. Global Rekovelle Epidemiology Of Clinical Indications
10. Rekovelle Market Regional And Country Analysis
11. Asia-Pacific Rekovelle Market
12. China Rekovelle Market
13. India Rekovelle Market
14. Japan Rekovelle Market
15. Australia Rekovelle Market
16. South Korea Rekovelle Market
17. Western Europe Rekovelle Market
18. UK Rekovelle Market
19. Germany Rekovelle Market
20. France Rekovelle Market
21. Eastern Europe Rekovelle Market
22. North America Rekovelle Market
23. USA Rekovelle Market
24. Canada Rekovelle Market
25. South America Rekovelle Market
26. Middle East Rekovelle Market
27. Africa Rekovelle Market
28. Rekovelle Market Competitive Landscape And Company Profiles
29. Global Rekovelle Market Pipeline Analysis
33. Rekovelle Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Rekovelle Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on rekovelle market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for rekovelle ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rekovelle market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Controlled Ovarian Stimulation; Polycystic Ovary Syndrome2) By Distribution Channel: Hospitals; Clinics; Pharmacies
3) By End User: Pediatric; Adult; Geriatric
Key Companies Profiled: Ferring Pharmaceuticals A/S
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Ferring Pharmaceuticals A/S
